Thursday, 14th February 31st Lorne Cancer Conference 2019

Introduction: Alex Swarbrick

• Hereditary predisposition to childhood brain tumors - Stefan Pfister
• Improved therapy for paediatric pineoblastoma by the disruption of cell cycle control - Clara Andradas Arias
• Translating cell cycle checkpoint kinase inhibitors into the clinic for medulloblastoma - Nick Gottardo
• A network-based druggable genome analysis identifies novel therapeutic targets for non-WNT medulloblastoma - Laura A Genovesi
• Precision or Poison: The Development of novel therapies for high risk childhood cancers - David Ziegler

• Stat3 suppresses primary tumour growth, but increases metastases in Myc-driven small cell lung cancer - Aleks Guanizo
• Mass cytometric (CyTOF) profiling of cell death in multiple myeloma reveals a new synergy between glucocorticoids and BH3 mimetic drugs - Daniel HD Gray
• Estrogen receptor (ER) positive luminal progenitors identified as the cancer cell of origin for ER+ breast cancer - Kara L Britt
• Mechanisms underlying uncontrolled genome doubling in breast cancer - Elizabeth Caldon
• Up-regulation of the recombination activating gene (RAG) and off-target V(D)J recombination drive oncogenic rearrangement in treatment-resistant chronic myeloid leukaemia  - Daniel Thomson
• Permutation based extraction of genotype-phenotype associations from heterogenous cancer genomes - Anthony Uren
• Therapeutic targeting of OLIG2 in high grade glioma by a novel drug candidate CT-179 - Charlotte CC Chen
• Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC - Natasha K Brockwell
• Proteomic profiling of human prostate cancer-associated fibroblasts (CAF) reveals LOXL2-dependent regulation of the tumor microenvironment - Natalie Lister
• Targeting the androgen receptor in estrogen receptor-driven breast cancer - Theresa E Hickey
• Identifying novel treatment options for women with aggressive, therapy-resistant ovarian carcinosarcoma     - Holly E Barker
• Mitochondria and Cancer  - Marcia Haigis

• Designing Novel Effective EGFRvIII CAR T cells for Glioblastoma - Rebecca C Abbott
• Colorectal cancer patient-derived xenografts for pre-clinical drug trials - Suad Abdirahman
• Identify breast cancer risk-associated lncRNAs that play a role in DNA damage repair - Nehal Abdou
• Protein glycosylation features of metastatic melanoma: the search for prognostic markers - Jodie L Abrahams
• JAK activation drives resistance to CDK4/6 inhibition in ER+ breast cancer - Sarah Alexandrou
• Selective Stat3 inhibition in the tumour microenvironment restrics gastrointestinal tumour growth - Mariah Alorro
• Investigating the contribution of legumain to oral cancer pain - Bethany M Anderson
• Dysregulated transcriptional response to differentiation signals in cohesin-mutant leukemia cells - Jisha Antony
• Using protein structure and function information to predict and understand variant pathogenicity - David B Ascher
• Calcium signalling in progression of Groups 3 and 4 medulloblastomas - Iman Azimi
• Oligonucleotide aptamers as alternative bio-recognition reagents for immunohistochemistry: The utility of ‘chemical antibodies’ in the detection of co-localised surface stemness markers in colorectal cancer xenografts and the identification of putative cancer stem cells - Michelle L Bauer
• The immunopeptidome of melanoma - Andreas Behren
• High-throughput microscope-based examination of total circulating cell population enables identification of tumour cells in lung cancer radiotherapy patients - Benjamin Blyth
• Platelets disrupt vasculogenic mimicry by cancer cells - Claudine Bonder
• Investigating the potential use of RNA polymerase 1 transcription inhibitors in the treatment of MDS - Daniela P Borges
• A cytokine-mediated cross talk between Tuft cells and group 2 innate lymphoid cells (ILC2) drives gastric tumourigenesis. - Michael Buchert
• Overcoming the Blood-Brain Barrier to Deliver Therapeutics to Brain Tumours - Bakhtiar Bukari
• The Function of DCLK1 isoforms in Gastric Cancer - Annalisa L.E. Carli
• Jumping genes and cancer progression. - Patricia Carreira
• Inhibition of the neuropeptide-Y signalling axis as a novel therapeutic option in pancreatic cancer - Cecilia Chambers
• Repurposing propranolol to improve the efficacy of doxorubicin on metastasis - Aeson Chang
• Molecular comparison of interval and screen-detected breast cancers - Dane Cheasley
• Cell lineage restricted MYC expression drives distinct subsets of Small Cell Lung Cancer   - Jasmine Chen
• Mechanisms of BMP4-mediated regulation of breast cancer metastasis - Lap Hing Chi
• Tumor exosomes: novel regulators of cancer cachexia   - Sai Vara Prasad Chitti
• Targeting the lysyl oxidases in pancreatic cancer - Jessica L Chitty
• Histone deacetylase inhibitors (HDACi) as a differentiation therapy for non-small cell lung adenocarcinoma   - Wai Chin Mr Chong
• Multiomics strategy to identify mechanisms that determine resistance and sensitivity to mutant p53 reactivator, APR-246 - Kenji Fujihara
• Identification of direct and indirect activators of the STING cytosolic DNA sensing pathway - Theresa Connor
• Understanding and visualising the role of extracellular matrix remodelling in cancer progression and metastasis - Thomas R Cox
• Investigating the role of FK506 binding protein 25 in breast cancer cell epithelial to mesenchymal transition - Tabitha M Cree
• The mechanism of synthetic lethality between BRCA1/2 and Fanconi anaemia E3 ligase activity - Wayne Crismani
• Heterogeneity in single-cell apoptotic signalling promotes chemoresistance in neuroblastoma - David R Croucher
• The genetic background of infant leukaemia reveals novel therapeutic targets - Mark N Cruickshank
• PI3K/AKT pathway dysregulation in breast cancer - Mariah P. Csolle
• Elucidating the role of a functional epithelial barrier for early diagnosis of oral lesions   - Charbel Darido
• Caspase-2 protects against ferroptotic cell death - Swati Dawar
• Comparing array and whole genome sequencing-derived homologous recombination deficiency score - Marc Xavier de Luca
• Loss of BCL-W does not impact the survival of human Burkitt and diffuse large B cell lymphoma cells - Sarah T Diepstraten
• MTCH2 and MARCH5 cooperate to control the turnover of the MCL1:NOXA complex - Tirta Djajawi
• Predicting immunotherapy treatment outcomes in melanoma patients - Jessica Da Gama Duarte
• Design and application of novel chemical probes to detect cathepsin X activation in oral cancer  - Laura Edgington-Mitchell
• c-Met activation leads to the establishment of a TGFβ receptor regulatory network required for bladder cancer invasion. - Pieter Eichhorn
• IL-33 signalling in innate immune cells drives gastric tumour growth in mice - Moritz Eissmann
• Epigenetic regulation of T cell effector function: Role of DOT1L in T cell immunity to cancer - Jessie Ellemor
• ­Characterising the role of caspase-3 loss in human colorectal cancer - Meg J Elliott
• The role of TIMP-2 in ovarian cancer chemoresistance - Ruth M Escalona
• An in vitro drug sensitivity testing platform for identifying personalised drug treatments for high risk childhood cancer patients - Tim W Failes
• Drug discovery and development using the ACRF Drug Discovery Centre - Greg M Arndt
• MILIP is a pan cancer-associated long noncoding RNA that links MYC to inactivation of p53 - Yuchen Feng
• Investigating the role of tumour-associated T cells in human colorectal cancer liver metastases - Kevin Aaron Fenix
• Deciphering the role of Mitochondrial STAT3 - Chamira Dilanka Fernando
• AURKA overexpression overcomes the ATM dependent checkpoint in melanoma - Madushan Fernando
• RNA polymerase I therapy: the second generation  - Rita Ferreira
• Plasma cell-free DNA concentration and outcomes in advanced prostate cancer patients treated with androgen signalling inhibitors - Heidi Fettke
• Prognostic and predictive utility of copy number variations (CNVs) in circulating tumor DNA (ctDNA) from metastatic castration-resistant prostate cancer (mCRPC) patients - Heidi Fettke
• Influence of Matrix Stiffness on Cancer Cell Metastatic Potential - Elysse C Filipe
• Unlocking somatic SNV and CNA calling with RNA-Seq - Christoffer Flensburg
• The role of prion protein expression and processing on epithelial to mesenchymal transition in colorectal cancer - Natalia NFM Fortunato de Miranda
• TotalSeq™, standardized oligo barcode antibody conjugates for highly-multiplexed immunophenotyping by single-cell sequencing - Kathryn Friend
• Understanding the role of a unique population of T-helper 17 cells in the pathogenesis of infection-induced colon cancer - Ka Yee Fung
• Characterisation of developmental pathways that drive metastatic progression of breast cancer at single cell resolution - David Gallego Ortega
• A network-based druggable genome analysis identifies novel therapeutic targets for non-WNT medulloblastoma - Laura A Genovesi
• Genome-wide loss of function screens to determine the molecular mechanism(s) underlying the nucleolar surveillance response - Amee J George
• Assessing how chemotherapy modulates the immune response in murine models of paediatric medulloblastoma. - Courtney George
• Inhibiting PRMT5 as a novel therapeutic approach for the treatment of melanoma - Prerana Ghosh
• Identifying novel cancer-associated stromal targets for the treatment of colorectal cancer - Krystyna Gieniec
• Delineating key autophagic markers in breast cancer cell Lines associated with an aggressive phenotype and autophagic inhibitor sensitivity.   - Charlett M Giuliani
• Fragment size characterization of cell-free DNA mutations from clonal hematopoiesis - Gerald Goh
• Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia - Jianan Gong
• Clinical Application of Circulating Tumour Cells and Circulating Tumour DNA in Uveal Melanoma - Elin S Gray
• ALK4 signalling suppresses NK cell function to aid tumour immune evasion - Fernando Guimaraes
• Microphthalmia-associated transcription factor (MITF) regulates dynamic heterogeneity and structural integrity in melanoma - Nikolas Haass
• ErbB2/Her2 Transcript Levels Subdivide Breast Cancer into Three Separate and Clinically Distinct Survival Cohorts - Daniel Harari
• Development of an EGFR aptamer for targeted glioblastoma treatment - Emma M Hays
• Investigating the Cellular and Immunoregulatory Effects of Activating the DNA Damage Response In A Murine Model Of Ovarian Cancer - Michael Hendley
• The delivery of doxorubicin to cancer cells using a DNA aptamer targeting EpCAM - Justin L Henri
• Predicting mutant p53-dependent pancreatic cancer spread via intravital imaging in the E-cadherin biosensor mouse - David Herrmann
• Harnessing the innate immune response to treat small cell lung cancer - Jonas Hess
• Mesenchymal transformation as a potential target of the microtubule dynamic inhibitors, eribulin, in fallopian tube derived/ovarian carcinosarcoma - Gwo Yaw Ho
• MicroRNA drugs for the treatment of high-risk neuroblastoma - Holly Holliday
• Combining ATR inhibition with chemotherapy and radiation enhances in vitro and in vivo cytotoxicity in medulloblastoma - Meegan Howlett
• “Immuno-flowFISH”: Diagnostic assessment of chromosomal abnormalities in phenotyped chronic lymphocytic leukaemia cells by imaging flow cytometry - Yeuk Lam Hui
• Reducing platelet count or function improves disease outcome in models of metastatic lung adenocarcinoma - Stephanie R Hyslop
• Targeting the cytoskeletal regulator AFAP1L1 to control sarcoma migration and invasion - Evan Ingley
• Longitudinal whole genome sequence studies in indolent CLL - Monirul Islam
• Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation - Sebastien Jacquelin
• Immunodeficient Zebrafish Xeno-transplantation  - Realla Jones
• Validating the Immuno-Oncology Potential of Large and Small Molecule Candidates and Combinations using in vitro BioMAP® Human Tumor Microenvironment Models - Shaun Jushun
• The tumour immune microenvironment in metaplastic breast cancer - Emarene Kalaw
• Understanding the basis for sex differences and inter-individual variability in the pharmacokinetics of therapeutic monoclonal antibodies - Lisa M Kaminskas
• Lymphatic exposure of monoclonal antibodies is two-fold higher in females compared to males in spite of similar plasma pharmacokinetics after intravenous dosing - Lisa M Kaminskas
• Loss of CBS promotes escape of AKT-induced senescence and involves in oncogenic transformation of gastric cancer in synergy with AKT - Jian Kang